Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma

被引:3
|
作者
Zganjar, Andrew [1 ]
Khanna, Abhinav [1 ]
Joyce, Dan [1 ]
Nichols, Paige [1 ]
Britton, Cameron [1 ]
Lohse, Christine M. [2 ]
Cheville, John C. [3 ]
Gupta, Sounak [3 ]
Potretzke, Aaron M. [1 ]
Thompson, R. Houston [1 ]
Leibovich, Bradley C. [1 ]
Boorjian, Stephen A. [1 ]
Sharma, Vidit [1 ]
机构
[1] Mayo Clin, Dept Urol, 200 First St SW, Rochester, MN 55901 USA
[2] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
来源
JOURNAL OF UROLOGY | 2024年 / 212卷 / 02期
关键词
kidney neoplasms; nephrectomy; renal cell carcinoma; POSTOPERATIVE PROGNOSTIC NOMOGRAM; ADJUVANT PEMBROLIZUMAB; RADICAL NEPHRECTOMY; PREDICTION; MANAGEMENT; RECURRENCE;
D O I
10.1097/JU.0000000000004030
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The AUA guidelines introduced a new risk group stratification system based primarily on tumor stage and grade to guide surveillance for patients treated surgically for localized renal cell carcinoma (RCC). We sought to evaluate the predictive ability of these risk groups using progression-free survival (PFS) and cancer-specific survival (CSS), and to compare their performance to that of our published institutional risk models. Materials and Methods: We queried our Nephrectomy Registry to identify adults treated with radical or partial nephrectomy for unilateral, M0, clear cell RCC, or papillary RCC from 1980 to 2012. The AUA stratification does not apply to other RCC subtypes as tumor grading for other RCC, such as chromophobe, is not routinely performed. PFS and CSS were estimated using the Kaplan-Meier method. Predictive abilities were evaluated using C indexes from Cox proportional hazards regression models. Results: A total of 3191 patients with clear cell RCC and 633 patients with papillary RCC were included. For patients with clear cell RCC, C indexes for the AUA risk groups and our model were 0.780 and 0.815, respectively (P < .001) for PFS, and 0.811 and 0.857, respectively (P < .001), for CSS. For patients with papillary RCC, C indexes for the AUA risk groups and our model were 0.775 and 0.751, respectively (P = .002) for PFS, and 0.830 and 0.803, respectively (P = .2) for CSS. Conclusions: The AUA stratification is a parsimonious system for categorizing RCC that provides C indexes of about 0.80 for PFS and CSS following surgery for localized clear cell and papillary RCC.
引用
收藏
页码:331 / 341
页数:11
相关论文
共 50 条
  • [21] Does knowing the risk of relapse in localized renal cell carcinoma matter?
    Wszolek, Matthew
    BJU INTERNATIONAL, 2019, 123 (02) : 201 - 202
  • [22] Recurrence risk groups after nephrectomy for renal cell carcinoma
    Polanco Pujol, L.
    Herranz Amo, F.
    Cano Velasco, J.
    Subira Rios, D.
    Moralejo Garate, M.
    Hernandez Cavieres, J.
    Barbas Bernardos, G.
    Bueno Chomon, G.
    Rodriguez Fernandez, E.
    Hernandez Fernandez, C.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (02): : 111 - 118
  • [23] Mayo Adhesive Probability Score Is Associated With Localized Renal Cell Carcinoma Progression-free Survival REPLY
    Thiel, David D.
    Davidiuk, Andrew J.
    Meschia, Camille
    Serie, Daniel
    Custer, Kaitlynn
    Petrou, Steven P.
    Parker, Alexander S.
    UROLOGY, 2016, 89 : 61 - 62
  • [24] The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
    Blute, ML
    Leibovich, BC
    Lohse, CM
    Cheville, JC
    Zincke, H
    BJU INTERNATIONAL, 2004, 94 (01) : 33 - 41
  • [25] Treatment of localized renal cell carcinoma
    Brinkmann, Isabel
    Stief, Christian G.
    Marcon, Julian
    NEPHROLOGIE, 2024, 19 (04): : 252 - 259
  • [26] Surgery of localized renal cell carcinoma
    Schnoeller, T. J.
    Schrader, M.
    Jentzmik, F.
    ONKOLOGE, 2015, 21 (01): : 22 - +
  • [27] Treatment of localized renal cell carcinoma
    Brinkmann, Isabel
    Stief, Christian G.
    Marcon, Julian
    UROLOGIE, 2024, : 176 - 183
  • [28] External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology
    Zigeuner, Richard
    Hutterer, Georg
    Chromecki, Thomas
    Imamovic, Arvin
    Kampel-Kettner, Karin
    Rehak, Peter
    Langner, Cord
    Pummer, Karl
    EUROPEAN UROLOGY, 2010, 57 (01) : 102 - 109
  • [29] Preoperative CT Radiomics Predicting the SSIGN Risk Groups in Patients With Clear Cell Renal Cell Carcinoma: Development and Multicenter Validation
    Jiang, Yi
    Li, Wuchao
    Huang, Chencui
    Tian, Chong
    Chen, Qi
    Zeng, Xianchun
    Cao, Yin
    Chen, Yi
    Yang, Yintong
    Liu, Heng
    Bo, Yonghua
    Luo, Chenggong
    Li, Yiming
    Zhang, Tijiang
    Wang, Rongping
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Identifying the risk of disease progression after surgery for localized renal cell carcinoma
    Abel, E. Jason
    Culp, Stephen H.
    Meissner, Matthew
    Matin, Surena F.
    Tamboli, Pheroze
    Wood, Christopher G.
    BJU INTERNATIONAL, 2010, 106 (09) : 1277 - 1283